SAB Biotherapeutics (SABS) Institutional Ownership → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free SABS Stock Alerts $4.40 +0.04 (+0.92%) (As of 04/24/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for SAB Biotherapeutics (NASDAQ:SABS)CurrentInstitutional OwnershipPercentage7.82%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$14.23MNumber ofInstitutional Sellers(last 12 months)0 Get SABS Insider Trade Alerts Want to know when executives and insiders are buying or selling SAB Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SABS Institutional Buying and Selling by Quarter Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! SAB Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/15/2024BVF Inc. IL9,178,282$6.31M0.2%N/A175.426% 2/14/2024Commodore Capital LP1,831,746$1.26M0.1%N/A35.024% 2/14/2024RTW Investments LP9,178,282$6.31M0.1%N/A175.493% 11/8/2023Pathstone Family Office LLC506,513$319K0.0%N/A0.968% 8/9/2023Institutional & Family Asset Management LLC192,027$159K0.0%+28.2%0.381% 2/2/2023Silver Oak Securities Incorporated51,941$31K0.0%N/A0.121% 11/7/2022Institutional & Family Asset Management LLC149,774$105K0.0%+91.7%0.348% 10/20/2022 First PREMIER Bank807,535$566K0.2%+23.8%1.877% 8/15/2022LGL Partners LLC23,000$33K0.0%N/A0.054% 8/3/2022AE Wealth Management LLC18,700$27K0.0%N/A0.044% 7/26/2022 First PREMIER Bank652,440$946K0.3%N/A1.519% 5/9/2022Qube Research & Technologies Ltd24,179$91K0.0%+43.8%0.056% 2/14/2022Radcliffe Capital Management L.P.546,658$5.52M0.1%N/A1.257% 2/14/2022ETF Managers Group LLC13,202$105K0.0%N/A0.030% 2/14/2022Institutional & Family Asset Management LLC78,115$610K0.1%N/A0.180% 2/10/2022Qube Research & Technologies Ltd16,817$131K0.0%N/A0.039% 2/9/2022Wolverine Asset Management LLC6,602$51K0.0%N/A0.015% 2/9/2022Alps Advisors Inc.50,306$393K0.0%N/A0.116% 2/3/2022Spectrum Management Group LLC5,030$39K0.0%N/A0.012% 2/1/2022Qube Research & Technologies Ltd16,817$131K0.0%N/A0.039% 1/19/2022 First PREMIER Bank832,555$6.50M1.7%N/A1.915% 1/18/2022Nadler Financial Group Inc.11,000$86K0.0%N/A0.025% 11/17/2021Tudor Investment Corp Et Al60,000$605K0.0%N/A0.406% (Data available from 1/1/2016 forward) SABS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SABS shares? During the previous two years, 10 institutional investors and hedge funds held shares of SAB Biotherapeutics. The most heavily invested institutionals were BVF Inc. IL ($6.31M), RTW Investments LP ($6.31M), Commodore Capital LP ($1.26M), First PREMIER Bank ($566K), Pathstone Family Office LLC ($319K), Institutional & Family Asset Management LLC ($159K), and Qube Research & Technologies Ltd ($91K).Learn more on SABS's institutional investors. What percentage of SAB Biotherapeutics stock is owned by institutional investors? 7.82% of SAB Biotherapeutics stock is owned by institutional investors. Learn more on SABS's institutional investor holdings. Which institutional investors have been buying SAB Biotherapeutics stock? Of the 10 institutional investors that purchased SAB Biotherapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BVF Inc. IL ($9.18M), RTW Investments LP ($9.18M), Commodore Capital LP ($1.83M), First PREMIER Bank ($807.54K), Pathstone Family Office LLC ($506.51K), Institutional & Family Asset Management LLC ($113.91K), and Silver Oak Securities Incorporated ($51.94K). How much institutional buying is happening at SAB Biotherapeutics? Institutional investors have bought a total of 21,717,273 shares in the last 24 months. This purchase volume represents approximately $15.46M in transactions. Related Companies: BCLI Institutional Ownership BLRX Institutional Ownership LIAN Institutional Ownership AVRO Institutional Ownership FRLN Institutional Ownership LPCN Institutional Ownership TCRT Institutional Ownership KALA Institutional Ownership ZIVO Institutional Ownership BYSI Institutional Ownership This page (NASDAQ:SABS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
